Australia Cardiac Resynchronization Therapy (CRT) Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator, CRT-Pacemaker), By End User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers, Other End Users) and Forecasts, 2026-2034

Last Updated: September 01, 2026 | Author: Debashree Bora | Format:

Australia Cardiac Resynchronization Therapy (crt) Market Size

The Australia Cardiac Resynchronization Therapy Market size was valued at USD 162 million in 2025 and is projected to grow from USD 177.36 million in 2026 to reach USD 366.04 million by 2034, growing at a CAGR of 9.48% during the forecast period 2026–2034.

Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.

The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.

Market Key Takeaways

Global Market Size & Growth

CRT-D dominates the market by Product.

Hospitals dominate the market by End-User.

Australia Cardiac Resynchronization Therapy (CRT) Market Size

Download a Free Sample To learn more about this report.

Product Insights

The Middle East and Africa market is segmented by CRT-D and CRT-P. CRT-D dominated the market over the forecast period.

Australia Cardiac Resynchronization Therapy (CRT) Market Size By Segments

Request Customizationto receive a tailored report.

End User Insights

The Middle East and Africa market is segmented by Hospitals, Cardiac Centre. Hospitals dominated the market over the forecast period.

Australia Cardiac Resynchronization Therapy (CRT) Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Analysis

International cardiology societies that recommend guidelines for identifying, managing, and preventing chronic heart failure in the nation include the Cardiac Society of Australia and New Zealand and the National Heart Foundation of Australia. The high prevalence of CHF, awareness campaigns by public & private health organizations, and investments by leading industry participants are anticipated to support market expansion in Australia. For instance, according to the Heart Foundation, 110,000 people in Australia have been diagnosed with heart failure. According to the Australian Institute of Health and Welfare, approximately 42,300 fatalities in 2019 were attributable to cardiovascular illnesses.

List of Key and Emerging Players in Australia Cardiac Resynchronization Therapy (CRT) Market

Abbott

Boston Scientific Corporation

Medtronic

Biotronik SE and Co. Kg

Microport Scientific Corporation

LivaNova PLC

Medico S.R.L.

Key Industry Developments

October 2025

BIOTRONIK partnered with the University of Sydney to co-develop digital and connected cardiac care solutions through 2028. The collaboration combines implanted cardiac device expertise, remote monitoring, and patient-facing digital tools, supporting improved follow-up and disease management for Australian patients using cardiac rhythm management and CRT devices.

Report Scope

Segmentation

By Product 2

CRT-Defibrillator
CRT-Pacemaker

By End User 4

Hospitals
Cardiac Centers
Ambulatory Surgical Centers
Other End Users

Competitive Coverage Abbott · Boston Scientific Corporation · Medtronic · Biotronik SE and Co. Kg · Microport Scientific Corporation

Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The Australian cardiac resynchronization therapy market size is growing at a CAGR of 9.48% from 2026 to 2034.

Technology advancement is the key driver for the growth of the optical transport network market.

Collaborative efforts is one of the upcoming trend in the optical transport network market.

The key players in the Australian cardiac resynchronization therapy market include Abbott, Boston Scientific Corporation, Medtronic, Biotronik SE and Co. Kg, Microport Scientific Corporation, LivaNova PLC, Medico S.R.L.

About the Author

Debashree Bora

Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.